Benitec Biopharma (BNTC) Return on Sales (2019 - 2024)
Benitec Biopharma (BNTC) has disclosed Return on Sales for 6 consecutive years, with 3073.71% as the latest value for Q1 2024.
- Quarterly Return on Sales fell 299320.0% to 3073.71% in Q1 2024 from the year-ago period, while the trailing twelve-month figure was 3073.71% through Mar 2024, down 278983.0% year-over-year, with the annual reading at 254.85% for FY2023, 984.0% down from the prior year.
- Return on Sales hit 3073.71% in Q1 2024 for Benitec Biopharma, down from 356.05% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 82.2% in Q2 2020 to a low of 3933.75% in Q3 2021.
- Historically, Return on Sales has averaged 1091.01% across 5 years, with a median of 272.07% in 2023.
- Biggest five-year swings in Return on Sales: tumbled -388482bps in 2021 and later surged 372271bps in 2022.
- Year by year, Return on Sales stood at 3261.0% in 2020, then skyrocketed by 94bps to 193.84% in 2021, then tumbled by -107bps to 401.36% in 2022, then rose by 11bps to 356.05% in 2023, then plummeted by -763bps to 3073.71% in 2024.
- Business Quant data shows Return on Sales for BNTC at 3073.71% in Q1 2024, 356.05% in Q4 2023, and 272.07% in Q3 2023.